Skip to main content
  1. Right Decisions
  2. DGRefHelp - NHS Dumfries & Galloway
  3. Sexual health
  4. Sexually transmitted infections (STIs)
  5. Back
  6. Syphilis
  7. Primary Syphilis
Important: please update your RDS app to version 4.7.3 Details with newsletter below.

Please update your RDS app to v4.7.3

We asked you in January to update to v4.7.2.  After the deployment planned for 27th February, this new update will be needed to ensure that you are able to download RDS toolkits even when the RDS website is not available. We will wait until as many users as possible have downloaded the new version before switching off the old system for app downloads and moving entirely to the new approach.

To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number. 

To update to the latest release:

 On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Right Decision Service newsletter: February 2025

Welcome to the February 2025 update from the RDS team

1.     Next release of RDS

 

A new release of RDS is planned (subject to outcomes of current testing) for week beginning 24th February. This will deliver:

 

  • Fixes to mitigate the recurring glitches with the RDS admin area and the occasional brief user interface outages which have arisen following implementation of the new distributed technology infrastructure in December 2024.

 

  • Capability to embed content from Google calendar, Google Maps, Daily Motion, Twitter feeds, Microsoft Stream into RDS pages.

 

  • Capability to include simple multiplication in RDS calculators.

 

The release will also incorporate a number of small fixes, including:

  • Exporting of form within Medicines Sick Day Guidance in polypharmacy toolkit
  • Links to redundant content appearing in search in some RDS toolkits
  • Inclusion of accordion headers alongside accordion text in search result snippets.
  • Feedback form on mobile app.
  • Internal links on mobile app version of benzo tapering tool

 

We will let you know when the date and time for the new release are confirmed.

 

2.     New RDS developments

There is now the capability to publish toolkits on the web with left hand side navigation rather than tiles on the homepage. To use this feature, turn on the “Toggle navigation panel” option at the top of the Page settings menu at toolkit homepage level – see below. Please note that publication to downloadable mobile app for this type of navigation is still under development.

The Benzodiazepine tapering tool is now available as part of the RDS toolkit for the national benzodiazepine prescribing guidance developed by the Scottish Government Effective Prescribing team. The tool uses this national guidance developed with a wide-ranging multidisciplinary group. This should be used in combination with professional judgement and an understanding of the needs of the individual patient.

3.     Archiving and version control and new RDS Search and Browse interface

Due to the intensive work Tactuum has had to undertake on the new technology infrastructure has pushed back the delivery dates again and some new requirements have come out of the recent user acceptance testing. It now looks likely to be an April release for the search and browse interface. The archiving and version control functionality may be released earlier. We’ll keep you posted.

4.     Statistics

At the end of January, Olivia completed the generation of the latest set of usage statistics for all RDS toolkits. If you would like a copy of the stats for your toolkit, please contact Olivia.graham@nhs.scot .

 

5.     Review of content past its review date

We have now generated reports of all RDS toolkit content that has exceeded its review date by 6 months or more. We will be in touch later this month with toolkit owners and editors to agree the plan for updating or withdrawing out of date content.

 

6.     Toolkits in development

Some important toolkits in development by the RDS team include:

  • National CVD prevention pathways – due for release end of March 2025.
  • National respiratory pathways, optimal cancer diagnostic pathways and cancer prehabilitation pathways from the Centre for Sustainable Delivery. We will shortly start work on the national cancer referral pathways, first version due for release via RDS around end of June 2025.
  • HIS Quality of Care Review toolkit – currently in final stages of quality assurance.

 

The RDS team and other information scientists in HIS have also been producing evidence summaries for the Scottish Government Realistic Medicine team, to inform development of national guidance around Procedures of Limited Clinical Value. This guidance will in due course be translated into an RDS toolkit.

 

7. Training sessions for new editors (also serve as refresher sessions for existing editors) will take place on the following dates:

  • Friday 28th February 12-1 pm
  • Tuesday 11th March 4-5 pm

 

To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)

 

To invite colleagues to sign up to receive this newsletter, please signpost them to the registration form  - also available in End-user and Provider sections of the RDS Learning and Support area.   If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot  If you would prefer not to receive future newsletters, please email Olivia.graham@nhs.scot and ask to be removed from the circulation list.

With kind regards

 

Right Decision Service team

Healthcare Improvement Scotland

 

 

Primary Syphilis

Warning

Incubation, Symptoms & Signs

Incubation period

21 days (9-90 days).

Symptoms and Signs

  • Characterised by an ulcer known as “the chancre”, in genital and nongenital sites, with localised lymphadenopathy.
  • The chancre is often painless with a clean base and indurated edges, BUT can be multiple and painful
  • Depending on the site, chancres may go unnoticed and heal spontaneously
  • Any anogenital ulcer should be considered to be syphilis until proven otherwise

Diagnosis

Dark ground microscopy, PCR testing and serology can help in the diagnosis of primary syphilis.

  • Where possible/ available perform dark ground microscopy of the serous exudate from any visible ulcers - slide taken to lab immediately. (Know if your laboratory can do dark ground microscopy) (NB: Dark ground microscopy is of no value in intra-anal or oral lesions. Only take a dark ground if you know how, get help if you don’t).
  • If dark ground microscopy is not available then consider sending the patient to the appropriate centre.
  • If a suspicious lesion is dark ground negative, consider bringing the patient back for up to two more dark grounds and repeat serology one week later.

 

  • PCR testing is available via the Regional Virus laboratories in Glasgow and Edinburgh: place the swab in viral transport medium and send to your microbiology department who will forward to the relevant virus lab. PCR is the preferred method for oral and other lesions where contamination with other commensal treponemes is likely. PCR is not a replacement for dark ground microscopy due to the time taken to get the result but should be done alongside dark ground microscopy if it is available. Please note all PCR ulcer swabs should be tested for HSV1/2 and T.pallidum

 

  • Serological tests in primary syphilis may be negative at this stage (usually become positive 2 weeks after the chancre appears).
  • If initial serology is inconclusive and there is a clinical suspicion, arrange repeat serology a week later and ideally at 6 weeks and 3 months
  • Avoid the use of antibiotics if possible at this stage if the diagnosis remains uncertain and the patient reports no exposure to syphilis. Treatment at this stage may prevent a serological response. Likewise if the patient is requiring antibiotics for another reason then this may affect syphilis serology

Treatment

Treatment must be initiated as soon as a diagnosis is reasonably established to limit infectivity and reduce risk of progression to secondary syphilis. Do not defer therapy because someone is uncertain about HIV testing or to bring patients back for further confirmatory tests. If you are happy with the clinical picture and the dark ground/ PCR is positive then start treatment immediately.

 

*Benzathine penicillin G 2.4 MU intramuscular
(as Extencilline 8ml) (NB unlicensed medication, named patient form may be needed)
For administration, see Preparation Instructions for Extencilline 2.4MU
PENICILLIN ALLERGY: Doxycycline 100mg twice daily orally for 14 day

Complications of Treatment

Jarisch Herxheimer reaction may occur at approximately 8 hours. This is an acute febrile illness with headache, myalgia, rigours which resolves in 24 hours and is common in early infection (advise rest, paracetamol). Usually this is not clinically important unless there is neurological or ophthalmogical
involvement or if the patient is pregnant. In these situations prednisolone and further monitoring may be advised (discuss with consultant)

Anaphylaxis – facilities for resuscitation must be present. Refer to local policy for further guidance

Patients should remain on the premises for 15 minutes after receiving their 1st injection to allow observation for immediate adverse reactions.

Partner Notification & Follow-up

Partner Notification

All patients diagnosed with syphilis need specialist input and to be seen by a sexual health adviser experienced in partner notification for Syphilis at diagnosis and at each follow up visit, until partner notification and any local surveillance is documented as complete.

Sexual partners within the last 3 months should be notified.

Follow-up

  • Clients should refrain from sexual contact until any lesions are fully healed and 2 weeks following treatment completion
  • Assess clinically at the end of treatment. Repeat serology at 3, 6 and 12 months after the end of treatment regime then if indicated, six monthly until VDRL/ RPR is negative or serofast.
  • If VDRL/RPR was positive at presentation expect a four-fold drop (2 dilution steps) in titre by six to twelve months.
  • If VDRL/RPR titre does not fall, or at any stage shows a >2-fold rise, discuss with senior doctor
  • Discharge only at 12 months if VDRL/RPR negative or if VDRL/RPR is serofast and has appropriately decreased as above
  • Ask permission to write to GP to confirm treatment complete, give patient a written summary of treatment with discharge serology 

Editorial Information

Last reviewed: 30/09/2022

Next review date: 30/09/2024

Author(s): West of Scotland Managed Clinical Network in Sexual Health Clinical Guidelines Group .

Version: 7.1

Approved By: West of Scotland Managed Clinical Network in Sexual Health